Answers are grounded in this paper and cite their sources.
Background/Objectives: Acute myeloid leukemia (AML) is characterized by substantial molecular and cellular heterogeneity, which contributes to variable treatment responses and disease relapse. Integrating transcriptomic evidence across complementary biological scales may facilitate the identification of robust disease-associated signatures for drug repurposing. This study aimed to define an AML transcriptional signature through integrated bulk and single-cell analyses and to identify and experimentally evaluate candidate repurposed compounds. Methods: Bulk transcriptomic and single-cell RNA-sequencing datasets were integrated using differential-expression analysis, weighted gene co-expression network analysis, pseudo-bulk analysis, and high-dimensional weighted gene co-expression network analysis. The esulting AML core signature was queried against the Connectivity Map and L1000 Fireworks Display databases to prioritize compounds with opposing transcriptional profiles. Albendazole (ABZ) and mebendazole (MBZ) were subsequently evaluated in MV4-11 and OCI-AML3 cells using viability assays, drug-treated RNA sequencing, RT-qPCR, flow cytometry, and Western blotting. Their in vivo activity was further assessed in disseminated AML xenograft models in combination with cytarabine. Results: Integrated transcriptomic analyses defined a 62-gene AML core signature comprising 18 upregulated and 44 downregulated genes. Perturbational screening identified a recurrent benzimidazole/microtubule-associated signal and prioritized ABZ and MBZ for experimental evaluation. Both compounds reduced AML-cell viability and induced apoptosis, S-phase accumulation, and changes in microtubule- and mitosis-associated markers. RNA-seq demonstrated significant coordinated reversal of the AML core signature in OCI-AML3 cells, whereas no significant overall reversal was observed in MV4-11 cells. In both xenograft models, ABZ + Ara-C or MBZ + Ara-C prolonged survival relative to vehicle-treated AML controls and were associated with reduced leukemic burden. Compared with Ara-C monotherapy (40 mg/kg/day), both combination regimens (20 mg/kg/day Ara-C) were associated with significantly shorter survival in OCI-AML3, whereas neither comparison reached statistical significance in MV4-11. Conclusions: Integrative transcriptomic drug repurposing identified ABZ and MBZ as candidate agents for AML. Their anti-leukemic activity was observed across both tested cellular models, whereas transcriptional signature reversal was cell-context-dependent. These findings support further pharmacological and mechanistic evaluation of benzimidazole anthelmintics in AML.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: